Compare JD.Com Inc (JD) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Nuvalent Inc — how do they compare? JD.Com Inc trades at $30.32 (market cap $41.80B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: JD.Com Inc is far larger — about 4.3× Nuvalent Inc's market cap, and JD.Com Inc pays a 3.27% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| JD | NUVL | |
|---|---|---|
Market Cap | $41.80B | $9.81B |
Sector | Consumer Cyclical | Technology |
52-Week High | $36.17 | $123.96 |
52-Week Low | $25.19 | $72.16 |
Enterprise Value | $27.96B | $8.52B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $30.43, up 2.73% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.74 exceeding expectations. Revenue reached $1.31 trillion in 2025, though net margins compressed to 1.05%. Technical indicators signal bullish momentum with the stock trading near key resistance levels.
Wall Street maintains strong bullish outlook with 69.6% buy ratings and $39.50 consensus target, representing 30% upside potential. Key risks include margin pressure, regulatory investigations, and Chinese market volatility. The company's aggressive buyback program and AI investments provide fundamental support despite competitive pressures.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
